The data presented highlights the strong predictive value of oxidative stress biomarker (4-HNE) levels with the rate of disease progression and survival in ALS patients from a longitudinal patient registry cohort.
Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".
The data presented highlights the strong predictive value of oxidative stress biomarker (4-HNE) levels with the rate of disease progression and survival in ALS patients from a longitudinal patient registry cohort.
Based on NAPT member survey data and other sources, “Temporal Evolution and Diagnostic Diversification of Patients Receiving Proton Therapy in the United States: A Ten-Year Trend Analysis (2012-21) from the National Association for Proton Therapy” largely debunks the misperception that proton therapy is used primarily as a treatment for prostate cancer.
"BENEFIT-01 Study was the first in a series of studies that speaks to our commitment to advancing and sharing the science behind SCS. It’s exciting to see these learnings realized as patients experience the positive impact of RESONANCE™ stimulation with our Prospera™ SCS system," said Todd Langevin.
Sensorion notes This gene therapy for patients suffering from otoferlin deficiency has been developed in the framework of RHU AUDINNOVE, a consortium composed of Sensorion with the Necker Enfants Malades Hospital, the Institut Pasteur, and the Fondation pour l’Audition. The project is partially financed by the French National Research Agency, through the “investing for the future” program (ref: ANR-18-RHUS-0007).
The Orlucent system will be the first to provide clinicians with a noninvasive direct measure of early intra-cellular activity and shows promise to transform the landscape of identifying melanoma at its earliest stage.
Identifai-Genetics advises the principal investigator in the study is world-renowned Professor Ronald Wapner, Director of Reproductive Genetics and Professor of Obstetrics and Gynecology at Columbia University Irving Medical Center.
Rivermark's FloStent System is a uniquely engineered nitinol stent that gently holds the prostatic urethra to restore normal urinary flow and provide rapid relief for patients with BPH. The system can be deployed during an outpatient procedure using any flexible cystoscope, offering a therapeutic intervention at the time of diagnosis with fewer complications and minimal recovery time.
SpineX notes the study affirms how after just eight weeks of SCiP therapy treatment, a 60-year-old woman living with CP is able to perform daily living activities with minimal external assistance.
ChemDiv CEO, Bill Farley. "This marks a significant step in harnessing intrinsic immunobiology pharmacologically, and we are excited about the potential impact it may have on revolutionizing cancer therapeutics."
The AVANT GUARD clinical trial will evaluate the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation System as a first-line treatment for persistent atrial fibrillation, the only trial to study the use of PFA as frontline therapy in patients with this form of AF.
By using this website you agree to accept Medical Device News Magazine Privacy Policy
